Plasma myostatin measured by a competitive ELISA using a highly specific antiserum

Clinica Chimica Acta; International Journal of Clinical Chemistry
Karl Florian WintgensFranz Paul Armbruster

Abstract

Understanding the (patho)physiology of the negative muscle regulator myostatin (Myo) is important for patients with skeletal muscle disorders or cardiac disease. However, a reliable tool for measuring plasma Myo immunoreactivity is still lacking. Human full-length proMyo was used to raise a polyclonal rabbit antiserum for a competitive Myo ELISA that was validated in patients with decompensated congestive heart failure (CHF) and in control patients (n=20 each). The Myo antiserum detected all subunits of human proMyo. The calibration curve showed an optimal range between 0.3 and 83.3 ng/ml (7.5-2100 pmol/l), with no cross-reactivity to growth differentiation factor-11, follistatin and follistatin-related gene protein. The inter-assay and intra-assay variances in human serum were ≤15% and ≤10%, respectively; the detection limit was 270 pg/ml (6.75 pmol/l). The assay showed excellent linearity in human plasma. Plasma NT-proBNP and Myo were significantly elevated in decompensated CHF compared with control patients and decreased significantly upon recompensating therapy. We describe the development of the first ELISA for myostatin immunoreactivity and its validation during recompensating therapy for CHF. This assay will be valuable ...Continue Reading

References

Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·A C McPherron, S J Lee
Dec 3, 2002·Nature·Sasha BogdanovichTejvir S Khurana
Dec 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Neil M WolfmanSe-Jin Lee
Oct 12, 2004·Annual Review of Cell and Developmental Biology·Se-Jin Lee
Jul 12, 2005·Journal of Biotechnology·Jannel AcostaMario Pablo Estrada
Jun 10, 2006·Circulation Research·Michael R MorissetteAnthony Rosenzweig
Sep 14, 2006·European Journal of Clinical Investigation·K G ShyuH Chang
Apr 25, 2008·Kidney International·Wai W CheungRobert H Mak
May 27, 2008·British Journal of Pharmacology·D J Wells
Jul 2, 2008·Endocrine Reviews·Buel D Rodgers, Dilip K Garikipati
Mar 30, 2010·European Journal of Heart Failure·Isaac GeorgeSimon Maybaum
Apr 14, 2010·Medicine and Science in Sports and Exercise·Dustin S HittelWilliam E Kraus
Aug 27, 2010·Revista española de cardiología·Elisabet ZamoraVicente Valle
Nov 26, 2010·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·S EhehaltUNKNOWN DISKUS-Study Group
Apr 7, 2011·European Journal of Heart Failure·Damien GrusonMichel F Rousseau
Apr 9, 2011·Journal of Cachexia, Sarcopenia and Muscle·Karsten LenkVolker Adams

❮ Previous
Next ❯

Citations

Apr 1, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Thomas Bernd Dschietzig
Sep 26, 2014·PloS One·Der-Sheng HanWei-Shiung Yang
Jul 9, 2016·International Journal of Cardiology·Takaaki FurihataHiroyuki Tsutsui
Jun 22, 2016·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Chun-Rong JuRong-Chang Chen
Apr 20, 2017·Medicine·Der-Sheng HanWei-Shiung Yang
Jul 18, 2012·The Journal of Clinical Endocrinology and Metabolism·Pawel SzulcLorenz C Hofbauer
Jan 13, 2017·Journal of the International Society of Sports Nutrition·Der-Sheng HanWei-Shiung Yang
Aug 19, 2021·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·Stefanie Kern-MatschillesAndreas Lechner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.